These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prevalence of and factors associated with persistent pain following breast cancer surgery. Gärtner R; Jensen MB; Nielsen J; Ewertz M; Kroman N; Kehlet H JAMA; 2009 Nov; 302(18):1985-92. PubMed ID: 19903919 [TBL] [Abstract][Full Text] [Related]
4. Breaking the Binary: The Approach to Chest Masculinizing Gender-Affirming Surgery in Trangender Men. Elias N; Rysin R; Kwartin S; Wolf Y Isr Med Assoc J; 2022 Jan; 24(1):20-24. PubMed ID: 35077041 [TBL] [Abstract][Full Text] [Related]
5. Clinical and neurophysiological evaluation of persistent sensory disturbances in breast cancer women after mastectomy with or without radiotherapy. Hojan K; Wojtysiak M; Huber J; Molińska-Glura M; Wiertel-Krawczuk A; Milecki P Eur J Oncol Nurs; 2016 Aug; 23():8-14. PubMed ID: 27456370 [TBL] [Abstract][Full Text] [Related]
7. Opioid Consumption After Gender-Affirming Mastectomy and Two Other Breast Surgeries. Robinson KA; Duncan S; Austrie J; Fleishman A; Tobias A; Hopwood RA; Brat G J Surg Res; 2020 Jul; 251():33-37. PubMed ID: 32109744 [TBL] [Abstract][Full Text] [Related]
8. Breast reconstruction with an expander prosthesis following mastectomy does not cause additional persistent pain: a nationwide cross-sectional study. Klit A; Mejdahl MK; Gärtner R; Elberg JJ; Kroman N; Andersen KG J Plast Reconstr Aesthet Surg; 2013 Dec; 66(12):1652-8. PubMed ID: 23911718 [TBL] [Abstract][Full Text] [Related]
9. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048 [TBL] [Abstract][Full Text] [Related]
10. [Mastectomy, the initial surgical procedure in transgender patients]. Piette E; Jaumotte M; Gilon Y; Nizet JL Rev Med Liege; 2022 Feb; 77(2):118-123. PubMed ID: 35143132 [TBL] [Abstract][Full Text] [Related]
11. Combining total laparoscopic hysterectomy and bilateral salpingo-oophorectomy with subcutaneous mastectomy in trans men: The effect on safety outcomes. Elfering L; van de Grift TC; Bouman MB; van Mello NM; Groenman FA; Huirne JA; Budiman IYW; Goijen LDJ; van Loenen DKG; Mullender MG Int J Transgend Health; 2020; 21(2):138-146. PubMed ID: 33015665 [No Abstract] [Full Text] [Related]
12. Quantifying the Psychosocial Benefits of Masculinizing Mastectomy in Trans Male Patients with Patient-Reported Outcomes: The University of California, San Francisco, Gender Quality of Life Survey. Alcon A; Kennedy A; Wang E; Piper M; Loeliger K; Admassu N; Lentz R; Kim EA Plast Reconstr Surg; 2021 May; 147(5):731e-740e. PubMed ID: 33890884 [TBL] [Abstract][Full Text] [Related]
13. Physical and Sociodemographic Features Associated With Quality of Life Among Transgender Women and Men Using Gender-Affirming Hormone Therapy. Silva ED; Fighera TM; Allgayer RM; Lobato MIR; Spritzer PM Front Psychiatry; 2021; 12():621075. PubMed ID: 34381383 [No Abstract] [Full Text] [Related]
14. Classification of Transgender Man's Breast for Optimizing Chest Masculinizing Gender-affirming Surgery. Wolf Y; Kwartin S Plast Reconstr Surg Glob Open; 2021 Jan; 9(1):e3363. PubMed ID: 33564589 [TBL] [Abstract][Full Text] [Related]